The Organic Demand Engine for Global Pharma
Built for Indian pharma exporters and global generics. SEO, AEO and GEO infrastructure that wins patient and HCP discovery in markets where paid Rx advertising is banned, across GLP-1, biosimilars, oncology, cardio-diabetes and OTC.
Founder With 20+ Years in Global Demand Generation. Pharma Team With 25+ Years of Industry Experience.
Our practice is led by founder Chirayu Parikh, with 20+ years of global demand generation experience, supported by a senior pharma team with 25+ years across end-to-end global pharma operations including formulation development, regulatory affairs (US FDA, EU EMA, CDSCO, GCC), manufacturing, supply chain, brand and export marketing, HCP engagement, and market access across US, EU, Gulf, Africa, LATAM and APAC. Every campaign is built on real-world pharma intuition from the team, paired with founder-led demand generation craft, not generic marketing playbooks.
Why Pharma, Why Now
GLP-1 is the headline. The pattern repeats across every off-patent molecule, every biosimilar launch, and every export market opening in the next 36 months.
GLP-1 global market by 2030 · India 34% CAGR
Export markets unlocking post patent expiry
India domestic semaglutide opportunity alone
GLP-1 (Semaglutide), $156B by 2030
March 2026 India patent expiry cleared 8+ generic brands; Rs 5,000 Cr domestic plus 100+ export markets opening across UAE, KSA, Canada, Africa.
Cardio-Diabetes Generics
Empagliflozin, Dapagliflozin, Sitagliptin going off-patent across LATAM and SEA, high-volume, recurring prescription categories.
Oncology & Biosimilars
Trastuzumab, Bevacizumab, Rituximab biosimilars, Biocon, Dr. Reddy's, Zydus leading. HCP-led demand generation is the only compliant route.
CNS, Respiratory & Rare Disease
Niche export categories where one well-ranked HCP page can capture an entire country's specialist demand for 24+ months.
OTC, Nutraceuticals & Wellness
Fully Direct-to-Consumer (DTC)-legal globally. Highest Return on Investment (ROI) surface for SEO/AEO, patient-facing content, reviews, and AI-cited brand answers.
Medical Devices & Diagnostics
CGMs, insulin pumps, point-of-care diagnostics, B2B2C with hospital procurement plus HCP recommendation loops.
The Three Barriers to Growth
Why traditional pharma marketing breaks in the AI era, and where the opening is.
The Crisis of Molecule Parity
With identical Application Programming Interfaces (APIs) across 8+ generic brands, traditional branding fails. Digital discoverability is the new competitive moat.
Heavy Regulatory Restrictions
CDSCO, FDA and EMA restrict patient-facing Rx ads. Paid digital is high-risk, non-compliant and non-scalable.
The 'Zero Presence' Vulnerability
Most generic players lack SEO infrastructure, JSON-LD schema and AI crawlability. Invisible to modern discovery.
The AI-Era Visibility Stack
Four layers, one compounding asset. Owned discovery across Google, ChatGPT, Perplexity, Gemini and LinkedIn, for every molecule, every market.
SEO & GEO-Targeted Infrastructure
Landing pages per drug × per city × per indication. Capture specific patient and HCP search intent without ad spend, the only scalable lever in markets that ban Rx ads.
AEO, Answer Engine Optimization
Structure content so ChatGPT, Perplexity, Gemini and Claude cite your brand as the definitive answer to clinical and patient queries. The new front page of the internet.
GEO, Generative Engine Optimization
llms.txt allowlists, JSON-LD Drug/MedicalCondition schema, and AI-bot crawlability so generative models find, understand and recommend your molecule.
HCP-Facing LinkedIn Engine
Educational-first content targeting endocrinologists, oncologists, cardiologists and specialists to drive professional brand recall and prescription preference.
AI Marketing, Decoded
Most Indian pharma teams haven't been briefed on AEO, GEO, schema or llms.txt. Here's the full glossary, what each term means, how it works, and why it matters for your molecule.
Getting your drug, brand or therapy page to rank #1 on Google when a patient or doctor searches.
70% of patient journeys start with a Google search. Ranking #1 is free, compounding traffic, no ad spend, no compliance review per click.
Optimizing content so ChatGPT, Perplexity and Gemini quote your brand as the answer when users ask clinical questions.
30%+ of search is shifting to AI chat. If your molecule isn't in the answer, you don't exist, regardless of Google rank.
Technical layer, llms.txt, JSON-LD Drug schema, MedicalCondition markup, that makes your content machine-readable for LLMs.
AI models can only recommend brands they can parse. Most generic players have zero GEO infrastructure, first-mover wins.
Building a full content + discoverability stack that creates patient and HCP demand without paid Rx advertising.
Central Drugs Standard Control Organisation (CDSCO), Food and Drug Administration (FDA) and European Medicines Agency (EMA) block paid Rx ads. Organic demand-gen is the only compliant, scalable growth engine for prescription pharma.
Educational, peer-reviewed content + LinkedIn distribution targeting specialists who prescribe your molecule.
One endocrinologist convinced of your semaglutide brand = 200+ prescriptions/month. Healthcare Professionals (HCPs) are the highest-leverage audience in pharma.
Invisible code that tells Google and AI 'this page is about Drug X, used for Condition Y, made by Company Z.'
Without it, AI guesses. With it, AI cites you. It's the single highest-ROI technical change in pharma SEO today.
Is This Allowed in Your Market?
Short answer: yes, organic SEO, AEO, GEO and HCP-led content are compliant across US, EU and emerging markets. Here's the breakdown.
United States (FDA)
- One of only 2 countries that permit Direct-to-Consumer Rx advertising (with NZ).
- Fair-balance, ISI, MedWatch reporting and PRC review mandatory on every asset.
- SEO/AEO on disease-awareness, HCP education and unbranded content is fully compliant and high-ROI.
European Union (EMA)
- EU Directive 2001/83/EC bans patient-facing Rx advertising across all 27 member states.
- Unbranded disease-awareness, HCP-only portals (DocCheck-style gating), and corporate content are permitted.
- Organic SEO/AEO targeting HCPs and unbranded patient education is the dominant compliant channel.
India (CDSCO) & Emerging Markets
- DMRA 1954 + DCA restrict patient-facing Rx promotion; OTC and wellness fully open.
- Gulf (SFDA, MOHAP), Africa (NAFDAC, KEBS) and LATAM mirror EU-style restrictions.
- Organic demand-gen + HCP LinkedIn is the only compliant, scalable model across these 100+ markets.
Note: Compliance summary for orientation. Every campaign goes through your internal PRC / medico-legal review and local regulatory affairs team before launch.
Who This Is For
Indian pharma majors with global ambitions, biosimilars, generics, specialty molecules. If your export team is launching across Gulf, Africa, LATAM or SEA, this is your stack.
Biocon Biologics
Biosimilars, insulin, oncology, immunology across 120+ markets
Sun Pharma
Generics + specialty, US, EM, India branded formulations
Dr. Reddy's
Generics, biosimilars, OTC, US, Russia, EU, India
Lupin
Specialty + generics, US, Japan, EMEA, growth markets
Cipla
Respiratory, anti-infectives, GLP-1 entrant, SA, EU, US
Zydus Lifesciences
Generics, biosimilars, vaccines, US, India, EM
Aurobindo
Generics, injectables, biosimilars, US, EU, growth
Torrent Pharma
Cardio-diabetes, CNS, India, Brazil, Germany, US
Regional Focus for Global Demand
Per-city, per-country landing pages with localized HCP and patient-education content.
India
212M diabetic adults; mass-market adoption.
Gulf / MENA
KSA = 30% of MENA GLP-1 market.
East & West Africa
Priority targets for Indian pharma exporters.
North America
High-value markets opening to generic competition.
LATAM
Cardio-diabetes generics, biosimilar tenders.
SEA
Fast-growing chronic-care prescription base.
Strategic Engagements
Start with one molecule or one export market. Scale across the portfolio.
Organic Global Demand Generation
Full SEO/Answer Engine Optimization and Generative Engine Optimization (AEO/GEO) infrastructure for patient + HCP discovery. Per-drug, per-city, per-indication landing pages with schema and AI crawlability.
Export Market Programs
Multilingual content + GEO page methodology for Africa, Gulf, LATAM and APAC. Country-localized HCP and unbranded patient content.
Full-Stack Telehealth & Web Build
End-to-end platforms for weight-loss, diabetes and specialty clinics, SEO, schema and HCP gating baked in from day one.
AI-Marketing Onboarding for Pharma Teams
Workshops + playbooks for export, brand and digital teams at Indian pharma majors. Demystify AEO, GEO, llms.txt, schema and HCP LinkedIn.
SEO vs AEO vs GEO, What's Different?
Three layers of discovery. One compounding asset. Here's how each works for a pharma brand launching a molecule globally.
| Dimension | SEO | AEO | GEO |
|---|---|---|---|
| Target Surface | Google, Bing search results | ChatGPT, Perplexity, Gemini answers | LLM training & retrieval pipelines |
| Primary Asset | Indexed web pages, backlinks | Q&A-structured, citable content | llms.txt, JSON-LD, clean HTML |
| Pharma Use Case | "Semaglutide brands in India" | "Best generic semaglutide for type-2 diabetes" | Drug + MedicalCondition schema |
| Time to Result | 3 to 6 months | 4 to 10 weeks | 2 to 6 weeks |
| Compliance Risk | Low (organic, no paid Rx ad) | Low (educational framing) | Negligible (technical layer) |
| Competitive Density | High, most brands present | Medium, early movers winning | Low, <5% of pharma has it |
| Decay Rate | Slow, multi-year compounding | Medium, model updates monthly | Slow, schema persists |
Who's Reading Your Pharma Pages?
The new crawlers that decide whether your molecule shows up in AI answers. Each needs explicit permission in llms.txt and robots.txt.
| AI Crawler | Operator | Powers | Pharma Visibility Impact |
|---|---|---|---|
| GPTBot | OpenAI | ChatGPT, GPT-5, Application Programming Interface (API) | Largest patient + HCP query surface globally |
| OAI-SearchBot | OpenAI | ChatGPT Search citations | Live citation of drug pages in answers |
| PerplexityBot | Perplexity AI | Perplexity answers + sources | Top citation engine for clinicians |
| ClaudeBot | Anthropic | Claude, enterprise assistants | Fast-growing in pharma enterprise stacks |
| Google-Extended | Gemini, AI Overviews, Vertex | Controls inclusion in Google AI answers | |
| Bingbot / Copilot | Microsoft | Bing, Copilot, Edge | Default in EU enterprise + healthcare IT |
| Meta-ExternalAgent | Meta | Llama, Meta AI | WhatsApp / Instagram patient assistants |
| Applebot-Extended | Apple | Siri, Apple Intelligence | Premium iOS patient demographics |
We configure your llms.txt, robots.txt, JSON-LD Drug + MedicalCondition schema, and an AI-friendly content architecture so every one of these agents can find, parse and cite your molecule.
What's Allowed, Where
Quick scan across US, EU and India for the channels your team is evaluating.
| Channel / Tactic | US (FDA) | EU (EMA) | India (CDSCO) | Gulf / Africa / LATAM |
|---|---|---|---|---|
| Organic SEO (HCP + unbranded) | ✅ Allowed | ✅ Allowed | ✅ Allowed | ✅ Allowed |
| AEO / GEO citations | ✅ Allowed | ✅ Allowed | ✅ Allowed | ✅ Allowed |
| Disease-awareness (unbranded) | ✅ Allowed | ✅ Allowed | ✅ Allowed | ✅ Allowed |
| DTC Rx branded ads | ✅ With ISI/PRC | ❌ Banned | ❌ Restricted | ❌ Mostly banned |
| HCP-only gated portals | ✅ Allowed | ✅ Allowed | ✅ Allowed | ✅ Allowed |
| LinkedIn HCP content | ✅ Allowed | ✅ Allowed | ✅ Allowed | ✅ Allowed |
| OTC / Nutraceutical DTC | ✅ Allowed | ✅ Allowed | ✅ Allowed | ✅ Allowed |
| Patient testimonials (Rx) | ⚠️ Heavy review | ❌ Banned | ❌ Restricted | ❌ Restricted |
Indicative. Local regulatory affairs and PRC review always final.
Three Pharma Audiences. One Connected Engine.
We engineer demand for Indian exporters into unregulated markets, Indian Active Pharmaceutical Ingredient (API) and bulk drug manufacturers selling globally, and international pharma companies sourcing from India.
Indian Pharma Exporters
Finished formulations into Africa, Commonwealth of Independent States (CIS), Latin America (LATAM), South East Asia (SEA) and Gulf Cooperation Council (GCC).
Read the PlaybookIndian API and Bulk Drug Manufacturers
Active Pharmaceutical Ingredients (APIs) and intermediates for international formulators and Contract Development and Manufacturing Organisations (CDMOs).
Read the PlaybookInternational Pharma Buyers Sourcing from India
Global formulators and procurement leaders short-listing Indian Active Pharmaceutical Ingredient (API) and Contract Development and Manufacturing Organisation (CDMO) partners.
Read the BriefWhere Global Demand Generation Has the Biggest Opening
Not every therapy area rewards organic demand generation equally. This matrix shows where Indian pharma exporters, Active Pharmaceutical Ingredient (API) manufacturers and biosimilar players see the highest Search Engine Optimization (SEO), Answer Engine Optimization (AEO) and Generative Engine Optimization (GEO) return.
| Therapy Area | Total Addressable Market by 2030 | SEO/AEO Competition | Demand-Gen Opportunity | Best Audience Fit |
|---|---|---|---|---|
| GLP-1 (Semaglutide, Tirzepatide) | $156B | Medium | Very High | Exporters + DTC OTC |
| Oncology Biosimilars | $78B | Low | Very High | HCP + Tender Markets |
| Cardio-Diabetes Generics | $112B | High | High | Exporters + Distributors |
| Respiratory (Inhalers, COPD) | $54B | Medium | High | Exporters + HCP |
| CNS & Rare Disease | $220B | Very Low | Very High | HCP + Specialist Networks |
| OTC & Nutraceuticals | $420B | Very High | Medium | DTC + Marketplace |
| API & Bulk Drugs | $280B | Very Low | Very High | International Buyers + CDMOs |
| Medical Devices (CGM, Insulin Pumps) | $96B | Medium | High | B2B2C + Hospital |
What We Build for Each Pharma Audience
Three distinct audiences, three distinct discoverability stacks. One unified Search Engine Optimization (SEO), Answer Engine Optimization (AEO) and Generative Engine Optimization (GEO) engine underneath.
| Deliverable | Indian Exporters (Finished Dosage) | Indian API / Bulk Drug Manufacturers | International Buyers Sourcing India |
|---|---|---|---|
| Primary Goal | Distributor leads + brand recall in unregulated markets | Drug Master File (DMF) inquiries from global formulators | Verified Indian Active Pharmaceutical Ingredient (API) and Contract Development and Manufacturing Organisation (CDMO) shortlist |
| Hero Pages | Per-molecule × per-country landing pages | Per-API × per-application × per-grade pages | Buyer-side comparison + due-diligence guides |
| Schema Stack | Drug + MedicalCondition + Offer | Product + Manufacturer + ChemicalSubstance | Organization + Service + Review + AggregateRating |
| Citation Engine | Patient queries on ChatGPT, Perplexity | Formulator queries on Claude, Perplexity, Bing Copilot | Procurement queries on ChatGPT, Gemini, Bing Copilot |
| LinkedIn Layer | HCP-facing brand authority | Quality, Regulatory and Business Development decision-maker reach | Buyer-side thought leadership for procurement heads |
| Compliance Surface | Local Drug Regulatory Authority + import license content | Drug Master File (DMF), Certificate of Suitability (CEP), Good Manufacturing Practice (GMP) badges | Audit history, inspection track record, ESG |
| Conversion Action | Distributor enquiry + WhatsApp | Drug Master File (DMF) request + Non-Disclosure Agreement (NDA) gate | Request for Proposal (RFP) + plant visit booking |
Unregulated vs Semi-Regulated vs Regulated Markets
The market access bar, time-to-revenue and discoverability investment differ sharply by tier. Most Indian exporters under-invest in tier-1 and over-invest in regulated markets.
| Dimension | Unregulated (Africa, Commonwealth of Independent States (CIS), parts of LATAM) | Semi-Regulated (Gulf Cooperation Council (GCC), South East Asia (SEA), Mexico) | Regulated (US, European Union (EU), Japan, Australia) |
|---|---|---|---|
| Registration Time | 3 to 9 months | 9 to 18 months | 24 to 60 months |
| Cost per Market Entry | $15K to $40K | $60K to $150K | $400K to $2M+ |
| Distributor Model | Country-exclusive importer | Distributor + local partner | Direct subsidiary or licensee |
| Demand-Gen ROI | Very High (low competition) | High | Medium (mature, ad-saturated) |
| Best Channel | SEO + WhatsApp + Distributor portal | SEO + Linkedin + HCP webinars | Disease-awareness + HCP gated portals |
| AI Citation Opportunity | Massive (under-served) | High | Moderate (Big Pharma dominates) |
| Time to First Revenue | 6 to 12 months | 12 to 24 months | 36+ months |
Tier-1 unregulated markets remain the fastest payback for Indian exporters, precisely where AI-era discoverability is still wide open.
Build In-House vs Agency vs Hybrid
How leading Indian pharma teams are staffing the AI-era visibility function.
| Dimension | Build In-House | Pure Agency | Hybrid (Recommended) |
|---|---|---|---|
| Time to Launch | 9 to 18 months | 4 to 8 weeks | 4 to 8 weeks |
| Annual Cost | $400K to $1.2M | $60K to $300K | $120K to $400K |
| Pharma-Specific Expertise | Hard to hire | Variable | Built-in (team with 25+ years pharma; founder with 20+ years demand gen) |
| AEO / GEO Capability | Rarely in-house yet | Top agencies only | Yes, core specialty |
| Compliance Risk | Lower (internal review) | Medium | Lower (PRC integration) |
| Scalability Across Markets | Slow | Fast | Fast |
| Knowledge Transfer to Team | Built organically | Limited | Workshops + playbooks |
The Invisible Pharma Brand: Why Indian Generics Are Losing the AI Search Layer , and the 90-Day Fix
A deep, end-to-end playbook for export marketing, brand and digital teams at Indian pharma majors. GLP-1, biosimilars, oncology, cardio-diabetes, the same model wins.
Read the Full Playbook →Model Your Pharma Demand-Gen ROI
Eight calculators built for Indian pharma exporters, API and bulk drug manufacturers, and international buyers sourcing from India. Plug your numbers in, see the model output instantly. No sign-up. No email gate.
Based on 35% average organic-search uplift seen in regulated Rx categories.
Models are directional. Final projections validated with your portfolio data, market access team and PRC review.
Pharma Demand Generation FAQ
Everything Indian pharma export, brand and digital teams ask before engaging on AI-era SEO, AEO and GEO.
Own the Patient & HCP Search Layer, Before Your Competition Does
Whether it's GLP-1, a biosimilar launch or a new export market, the same organic demand-generation model wins. Let's map the opportunity for your portfolio.
Glossary of Acronyms Used on This Page
A quick reference for the abbreviations that appear above, organised for export, brand, regulatory and digital readers.
- AEO
- Answer Engine Optimization
- AE
- Adverse Event
- AI
- Artificial Intelligence
- CDMO
- Contract Development and Manufacturing Organisation
- CEP
- Certificate of Suitability (European Pharmacopoeia)
- CIS
- Commonwealth of Independent States
- DMF
- Drug Master File
- GMP
- Good Manufacturing Practice
- NDA
- Non-Disclosure Agreement
- RFP
- Request for Proposal
- RFQ
- Request for Quotation
- APAC
- Asia Pacific
- API
- Active Pharmaceutical Ingredient
- CAGR
- Compound Annual Growth Rate
- CDSCO
- Central Drugs Standard Control Organisation (India)
- CNS
- Central Nervous System
- CTA
- Call to Action
- DCA
- Drugs Control Administration
- DMRA
- Direct Marketing and Regulatory Affairs
- DTC
- Direct-to-Consumer
- EMA
- European Medicines Agency
- EMEA
- Europe, Middle East and Africa
- EU
- European Union
- FAQ
- Frequently Asked Questions
- FDA
- Food and Drug Administration (United States)
- GCC
- Gulf Cooperation Council
- GEO
- Generative Engine Optimization
- GLP-1
- Glucagon-Like Peptide-1
- GPT-5
- Generative Pre-trained Transformer, version 5
- HCP
- Healthcare Professional
- ISI
- Important Safety Information
- KEBS
- Kenya Bureau of Standards
- KSA
- Kingdom of Saudi Arabia
- LATAM
- Latin America
- LLM
- Large Language Model
- MENA
- Middle East and North Africa
- MOHAP
- Ministry of Health and Prevention (United Arab Emirates)
- NAFDAC
- National Agency for Food and Drug Administration and Control (Nigeria)
- OTC
- Over-the-Counter
- PRC
- People's Republic of China
- ROI
- Return on Investment
- SEA
- South East Asia
- SEO
- Search Engine Optimization
- SFDA
- Saudi Food and Drug Authority
- UAE
- United Arab Emirates
- US
- United States
Regulator names and jurisdictional terms reflect the body of work referenced in this page. Always validate the latest naming with the relevant national authority before publishing market-facing collateral.